Cantor Fitzgerald Forecasts MREO FY2025 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0.08) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. assumed coverage on shares of Mereo BioPharma Group in a research note on Thursday. They set an “overweight” rating and a $7.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Wednesday, March 26th. Lifesci Capital assumed coverage on Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on Mereo BioPharma Group in a research note on Friday, December 6th. They issued a “buy” rating and a $7.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Mereo BioPharma Group has an average rating of “Buy” and a consensus target price of $7.71.

Mereo BioPharma Group Price Performance

NASDAQ:MREO opened at $2.30 on Monday. Mereo BioPharma Group has a 1 year low of $2.22 and a 1 year high of $5.02. The business has a fifty day simple moving average of $2.72 and a two-hundred day simple moving average of $3.48. The company has a market capitalization of $356.84 million, a P/E ratio of -38.33 and a beta of 1.03.

Mereo BioPharma Group (NASDAQ:MREO) last released its earnings results on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03).

Institutional Investors Weigh In On Mereo BioPharma Group

Large investors have recently made changes to their positions in the business. Fred Alger Management LLC boosted its holdings in Mereo BioPharma Group by 108.1% in the third quarter. Fred Alger Management LLC now owns 102,582 shares of the company’s stock valued at $422,000 after acquiring an additional 53,278 shares in the last quarter. Janus Henderson Group PLC boosted its position in Mereo BioPharma Group by 56.7% during the 3rd quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock valued at $50,865,000 after acquiring an additional 4,464,984 shares in the last quarter. Polar Asset Management Partners Inc. raised its position in shares of Mereo BioPharma Group by 36.0% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 198,300 shares of the company’s stock worth $815,000 after acquiring an additional 52,500 shares in the last quarter. State Street Corp purchased a new stake in Mereo BioPharma Group in the third quarter worth $195,000. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of Mereo BioPharma Group by 15.8% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock valued at $20,952,000 after buying an additional 696,408 shares in the last quarter. 62.83% of the stock is currently owned by institutional investors.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.